Alle Aktivitäten

Objectives: To prospectively evaluate the effect of guselkumab through 48 weeks across various clinical outcomes in subgroups of patients with …Den ganzen Artikel lesen

J Cutan Med Surg. 2024 Dec 14:12034754241302827. doi: 10.1177/12034754241302827. Online ahead of print. ABSTRACT BACKGROUND: Tildrakizumab is an interleukin-23 inhibitor approved in Canada in 2021 for the treatment of adults with moderate-to-severe plaque psoriasis. OBJECTIVES: To evaluate real-world effectiveness of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis in Canada. METHODS: A multicenter, retrospective study was conducted in Canada in adults with moderate-to-severe plaque psoriasis for ≥1 year treated with tildrakizumab for ≥12 weeks. Effectiveness was evaluated from proportions of patients achieving ≥75%/≥90%/100% improvement from baseline in Psoriasis Area and Severity Index (PASI 75/90/100 response) and Physician Global Assessment (PGA) 0 or 1 at weeks 16 (±4), 24 (±8), and 48 (±12). Subgroup analyses were performed based on prior biologic use and special site involvement. RESULTS: The study included 75 patients (mean age, 50.5 years; 52.0% female; 82.7% bio-naïve; 73.3% with special site involvement). Absolute mean (standard deviation) PASI score improved from 16.1 (6.7) at baseline to 1.3 (1.7) at the week 48 (91.7% improvement), 95.7%/69.6%/34.8% of patients achieved PASI 75/90/100 response, and 93.0% achieved PGA 0/1 at the week 48. In subgroup analyses, 94.7%/71.1%/34.2% of bio-naïve patients, 100.0%/62.5%/37.5% of bio-experienced patients, 100.0%/71.4%/28.6% of patients with special site involvement, and 81.8%/63.6%/54.6% of patients without special site involvement achieved PASI 75/90/100 response, and 87.5%, 94.3%, 97.0%, and 80.0% of patients, respectively, achieved PGA 0/1 at the week 48. None of the differences among subgroups were statistically significant; however, patient numbers were too small to support robust conclusions. CONCLUSIONS: Tildrakizumab is effective for the treatment of moderate-to-severe plaque psoriasis in adults in a real-world setting in Canada. PMID:39673433 | DOI:10.1177/12034754241302827 Den ganzen Artikel lesen

Arch Dermatol Res. 2024 Dec 14;317(1):125. doi: 10.1007/s00403-024-03607-8. ABSTRACT The genetic causality between cathepsin levels and autoimmune diseases (ADs) bidirectionally was investigated and the associated cancer risk was explored with Mendelian randomization. Mendelian randomization analyses were used to explore causal associations between cathepsin and 14 ADs. The final results came from a meta-analysis of two datasets to get a robust result. Furthermore, the potential carcinogenic effects of reduced cathepsin levels were explored. Sensitivity analyses were used to evaluate the robustness of the results. Based on the Mendelian randomization analysis, it was found that lower levels of specific cathepsins were associated with reduced risk of ADs. Reduced cathepsin E levels were linked to decreased susceptibility to psoriasis and a potential reduction in breast cancer risk. Reduced cathepsins G and L2 showed an inhibitory effect on psoriasis without increasing cancer risk. These results emphasized the genetic causal connection between cathepsin and ADs. Targeting cathepsins may be beneficial in treating ADs, but potential oncogenic effects must be considered to provide a basis for safer therapeutic strategies. PMID:39673556 | DOI:10.1007/s00403-024-03607-8 Den ganzen Artikel lesen

Arch Dermatol Res. 2024 Dec 14;317(1):115. doi: 10.1007/s00403-024-03550-8. ABSTRACT Psoriasis is a chronic, relapsing, inflammatory skin disease that is caused by the immune system. Amygdalin possesses immune-modulating and anti-inflammatory effects. To explore the possible effects of amygdalin on psoriasis and its pathogenesis of action, we examined the effects of amygdalin on imiquimod-induced psoriasis, tape-stripping-induced skin barrier disruption, and investigated the potential mechanism of action in vitro. The fact that amygdalin could reduce the thickness of the epidermis and inflammatory cell infiltration in two animal models inhibited the production of IL-1β, IL-6, and TNF-a, and the expression of filaggrin, involucrin, and keratin10 was increased. Also, in IL-17 A and TNF-α induced HaCaT, amygdalin inhibits the expression of IL-6, IL-1β, and TNF-a, promoting the expression of skin barrier recovery-related proteins flaggrin, involucrin, and keratin10. Combined in vivo and in vitro experiments suggest that amygdalin modulates inflammation and the skin barrier in psoriasis. The same study also conducted a preliminary mechanistic exploration and found that amygdalin inhibited the phosphorylation of the p38MAPK signaling pathway. In conclusion, Amygdalin can alleviate psoriasis lesions and improve skin barrier impairment, and the research provides an experimental basis for its future development as a drug candidate for psoriasis therapy. PMID:39673560 | DOI:10.1007/s00403-024-03550-8 Den ganzen Artikel lesen

Arch Dermatol Res. 2024 Dec 14;317(1):118. doi: 10.1007/s00403-024-03617-6. ABSTRACT Ulcerative colitis (UC) and psoriasis are highly correlated clinically; however, it is unclear whether they have a common pathophysiological mechanism. The purpose of this study is to investigate the important molecules and pathways that mediate the coexistence of UC and psoriasis through quantitative bioinformatics analysis of public RNA-sequencing databases. The UC (GSE38713) and psoriasis (GSE30999) datasets were downloaded from the Gene Expression Omnibus database. Differentially expressed genes were analysed using the "limma" package and their biological functions were investigated using Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes. The Search Tool for the Retrieval of Interacting Genes database was used to create the protein-protein interaction (PPI) network, which was visualised by Cytoscape. The CytoHubba plugin was used to select the hub genes. The hub genes of psoriasis and UC were verified in GSE75214, GSE78097, GSE14905, and GSE87466. The predicted value of the hub gene was evaluated by the receiver operating characteristic curve (ROC). Gene Set Enrichment Analysis (GSEA) and immune infiltration were performed for the hub genes. Finally, we performed transcription factor (TF)-gene interaction network analysis, TF-miRNA co-regulation network analysis and candidate drug prediction. A total of 114 genes (89 ascending genes and 25 descending genes) with similar expression trends between UC and psoriasis were identified. Enrichment analysis revealed that the two signaling pathways were primarily related to immune and inflammatory responses. PPI network screened 13 hub genes (IL-1B, CXCL10, TLR2, CD274, CXCR2, CXCL9, MMP9, CXCL1, CASP1, IL-7R, IL-1RN, CCL18 and LCN2). Using NetworkAnalyst, we constructed a co-regulatory network diagram of TF-gene and TF-miRNA. Finally, diacerein was predicted to be effective in the treatment of UC and psoriasis. Our research revealed the common pathogenesis of UC and psoriasis, and examined the hub genes, TF and miRNA and potential therapeutic drugs (diacerein). These findings may provide new perspectives for further mechanism research and clinical treatment. PMID:39673621 | DOI:10.1007/s00403-024-03617-6 Den ganzen Artikel lesen

Hum Immunol. 2024 Dec 13;86(1):111218. doi: 10.1016/j.humimm.2024.111218. Online ahead of print. ABSTRACT BACKGROUND: Immunosenescence, characterized by age-related changes in the immune system, may contribute to the onset and progression of psoriasis, a condition whose incidence increases with age and often requires intensified medication in older patients. METHODS: This study utilized bioinformatics analyses to identify differentially expressed immunosenescence-related genes in psoriasis patients from the GEO database. Enrichment, correlation, and interaction network analyses were conducted to explore their involvement in immune and inflammation pathways. Machine learning models were employed to predict psoriasis onset and validated using external datasets. Patient stratification based on gene expression patterns assessed differential responses to biologic inhibitors targeting specific genes. RESULTS: Immunosenescence emerged as a significant factor in psoriasis pathogenesis, with genes such as BACH2 potentially influencing T cell activation and disease outcomes. Lower BACH2 expression levels were associated with poorer treatment responses in psoriasis patients. CONCLUSIONS: This study sheds light on immunosenescence-related mechanisms in psoriasis, suggesting BACH2 as a potential disease diagnosis biomarker. Further research into BACH2's role in psoriasis pathophysiology is warranted to advance tailored treatment strategies. PMID:39673814 | DOI:10.1016/j.humimm.2024.111218 Den ganzen Artikel lesen

J Trace Elem Med Biol. 2024 Dec 10;87:127580. doi: 10.1016/j.jtemb.2024.127580. Online ahead of print. ABSTRACT BACKGROUND: Trichophyton rubrum is a widespread human pathogenic fungus, colonizing keratinized tissue of outer body-parts. Thereby, the pathogen is relying on nutrients available from the host. The invasive mechanism of the pathogen is relaying on secreted proteases, which hydrolyze skin-proteins for subsequent up-take. METHODS: In this study, we analyzed the gene expression of secreted proteases by RNAseq. In the results, we show the expression profile of 31 secreted protease genes under three conditions: keratin medium and keratin medium with trace-elements or with glucose. RESULTS: By adding trace-elements to keratin medium, the expression of secreted proteases increased from 1.8 % to 3.3 %. Across all groups of secreted proteases, higher expression was observed. The genes SUB4, MEP1, MEP3, MEP5, MEP9, LAP1, LAP2 and MCPA were significantly stronger expressed, whereby MEP5 (∼6 fold) and SUB4 (∼5.8 fold) were strongest up-regulated. DISCUSSION: We discuss the influence and significance of trace-elements on secreted proteases. Further, we speculate about the disturbed nutritional immunity in psoriatic and atopic skin as factor for increased risk of getting severe T. rubrum infections. PMID:39673825 | DOI:10.1016/j.jtemb.2024.127580 Den ganzen Artikel lesen

Explore (NY). 2024 Dec 10;21(1):103098. doi: 10.1016/j.explore.2024.103098. Online ahead of print. ABSTRACT INTRODUCTION: Psoriasis is a chronic inflammatory skin disease that can present in various phenotypes, with the most common form being plaque psoriasis. Currently, no type of psoriasis can be cured, and existing treatment options are associated with certain safety concerns. In recent years, traditional Chinese medicine has achieved great results in treating psoriasis. Cupping therapy is a widely used method in China. In this case, the combination of moving cupping therapy and acupoint bloodletting has demonstrated a favorable therapeutic effect on plaque psoriasis. CASE PRESENTATION: A 35-year-old male diagnosed with plaque psoriasis for 20 years, presented with generalized itchy, erythematous, and scaly skin. The patient underwent moving cupping therapy combined with acupoint bloodletting once every other day, three times per week, for a total duration of 8 weeks. After treatment, the erythema, plaques, and scales on the patient's entire body had mostly resolved. The Psoriasis Area and Severity Index (PASI) score decreased from 50 to 5, the Body Surface Area (BSA) improved from 60 % to 4 %, and the Dermatology Life Quality Index (DLQI) decreased from 17 to 2 points. No relapse was observed during the 6-month follow-up. CONCLUSION: This case demonstrates that moving cupping therapy combined with acupoint bloodletting is well tolerated and effective in relieving skin lesion symptoms and improving the quality of life in patients with plaque psoriasis. As a cost-effective adjunctive therapy, moving cupping therapy combined with acupoint bloodletting holds promise as a non-pharmacological treatment option for plaque psoriasis. PMID:39674053 | DOI:10.1016/j.explore.2024.103098 Den ganzen Artikel lesen

J Pediatr. 2024 Dec 12:114436. doi: 10.1016/j.jpeds.2024.114436. Online ahead of print. ABSTRACT OBJECTIVES: To examine pediatrician diagnostic skill development of dermatology image-based cases via a web-based tool and to determine case-level variables that were associated with diagnostic error. STUDY DESIGN: This was a multi-center, prospective, cross-sectional study. A convenience sample of pediatric trainees and attendings were eligible for participation. Using a web-based tool, physicians practiced 334 pediatric dermatology image-based cases until they achieved a performance standard. Participants identified whether the case was concerning, the morphologic category, and the specific diagnosis. After every case, participants received corrective feedback and their progress towards the performance standard. RESULTS: Among 185 participants, there was a significant improvement in diagnostic performance in classifying concerning vs. non-concerning (+19.2% [95% CI 17.7, 20.6]), morphologic category (+17.9% [95% CI 16.5, 19.3]), and specific diagnosis (+25.2% [95% CI 23.4, 26.7]). The median number of cases required to achieve the performance standard was 142 (IQR 96, 209; min 58, max 330), with a median time to achievement of 57.3 minutes (IQR 38.7, 84.3). Based on 38,502 case interpretations, children with darker versus lighter skin color had a lower odds of correct identification of "concerning" (OR=0.87; 95% CI 0.83, 0.93), morphologic category (OR=0.91; 95% CI 0.85, 0.97), and specific disease (OR=0.96; 95% CI 0.90; 0.99). Fewer than 60% of participants correctly identified bullous variations of diseases, psoriasis, herpes infections, and non-specific viral infections. CONCLUSIONS: The deliberate practice of dermatologic presentations in the context of an education intervention significantly and efficiently improved pediatrician diagnostic ability. The specific diagnostic challenges identified also provide opportunity for targeted learning opportunities in these areas. PMID:39674540 | DOI:10.1016/j.jpeds.2024.114436 Den ganzen Artikel lesen

RMD Open. 2024 Dec 12;10(4):e004494. doi: 10.1136/rmdopen-2024-004494. ABSTRACT OBJECTIVES: To prospectively evaluate the effect of guselkumab through 48 weeks across various clinical outcomes in subgroups of patients with psoriatic arthritis (PsA) and inadequate response to tumour necrosis factor inhibitors (TNFi-IR) from the phase 3b COSMOS trial. Subgroups were defined by baseline demographics, disease characteristics and prior/ongoing therapies. METHODS: Patients with active PsA (tender joint count (TJC) and swollen joint count (SJC) both ≥3) and TNFi-IR were randomised 2:1 to receive guselkumab 100 mg at week 0, week 4, then every 8 weeks through week 44 or to placebo with cross-over to guselkumab 100 mg at week 16 (early escape) or week 24 (planned). Guselkumab effect on joints (American College of Rheumatology (ACR) 20/50/70, enthesitis, dactylitis), skin (Psoriasis Area and Severity Index 90/100, Investigator's Global Assessment 0/1), patient-reported outcomes (PROs) (Functional Assessment of Chronic Illness Therapy-Fatigue, Health Assessment Questionnaire-Disability Index) and composite outcome measures (PsA Disease Activity Score low disease activity, minimal disease activity) were evaluated by baseline patient age, sex, body mass index, SJC, TJC, PsA duration, %body surface area, C reactive protein, pain Visual Analogue Scale, number of prior TNFi and discontinuation reason, and conventional synthetic disease-modifying antirheumatic drug status. Results are descriptive only. RESULTS: Baseline characteristics were similar between guselkumab (n=189) and placebo (n=96) groups. The benefit of guselkumab over placebo in achieving ACR 20 (primary endpoint; 50% vs 28%) and ACR 50 (23% vs 8%) response at week 24 was observed within all subgroups. Furthermore, response rates in the guselkumab group increased between week 24 and week 48 within almost all subgroups. Similar response patterns at week 24 and through week 48 were observed across various clinical outcomes. CONCLUSIONS: Guselkumab every 8 weeks led to consistent improvements through week 24 in joint, skin, PRO and composite outcomes versus placebo across diverse baseline-defined subgroups of TNFi-IR patients with PsA. Response rates increased or were durable through week 48 within most subgroups. PMID:39672591 | DOI:10.1136/rmdopen-2024-004494 Den ganzen Artikel lesen

Psychol Health. 2024 Dec 13:1-29. doi: 10.1080/08870446.2024.2434483. Online ahead of print. ABSTRACT BACKGROUND: Chronic skin conditions are common in youth. The developmental transition to young adulthood involves social, psychological and physical changes. Adolescents with chronic skin conditions may experience greater challenges than their healthy peers due to the addition of managing and coping with their condition. OBJECTIVE: This study explored experiences of transition from adolescence to adulthood in the context of chronic skin conditions. METHOD: Semi-structured interviews were conducted with seven young adults with chronic skin conditions (eczema, psoriasis, hidradenitis suppurativa). An interpretative phenomenological analysis methodological approach was used. RESULTS: Six themes were generated: (1) Navigating a difficult medical journey; (2) Managing a chronic skin condition is all-consuming; (3) Living with a chronic skin condition can be physically limiting; (4) Distressed, isolated and abnormal: How my skin makes me feel; (5) What is wrong with you? Experiences of stigma because of my skin; and (6) The resilience journey when living with a chronic skin condition. CONCLUSIONS: Findings highlight the difficulties experienced by young dermatology patients, particularly during adolescence, including challenges with healthcare providers, mobility disruptions and stigmatisation. Findings offer insight into how young people can be supported during their transition into adulthood, for example, treating skin conditions with a psychodermatological approach. PMID:39673073 | DOI:10.1080/08870446.2024.2434483 Den ganzen Artikel lesen

The Global Burden of Disease (GBD) study aims to characterize the worldwide prevalence and morbidity of major diseases, while PatientsLikeMe (PLM) is …Den ganzen Artikel lesen

Background: Cardiovascular comorbidity increases morbidity and mortality in psoriasis. Systemic treatments, particularly biologics, are effective in …Den ganzen Artikel lesen

Machado-Pinto J, Diniz Mdos S, Bavoso NC. Machado-Pinto J, et al. An Bras Dermatol. 2016 Jan-Feb;91(1):8-14. doi: 10.1590/abd1806-4841.20164169. An …Den ganzen Artikel lesen

Clin Cosmet Investig Dermatol . 2024 Nov 9;17:2523–2531. doi: 10.2147/CCID.S492053 Yizi Jiang 1First Clinical Medical College, Guizhou University of …Den ganzen Artikel lesen

Jomana Al Attar, Corresponding Author Jomana Al Attar [email protected] Department of Dermatology, Dermatological Medical Rehabilitation Centre, …Den ganzen Artikel lesen

Front Med (Lausanne) . 2024 Oct 29;11:1458394. doi: 10.3389/fmed.2024.1458394 Max Nordgren 1Diagnostic Center Dermatology, Malmö, Sweden 2Deparment of …Den ganzen Artikel lesen

JAAD Int . 2024 Aug 27;17:160–162. doi: 10.1016/j.jdin.2024.07.013 Mathias Tiedemann Svendsen, MD, PhD aDepartment of Clinical Research, University of …Den ganzen Artikel lesen

Acta Derm Venereol . 2024 Nov 20;104:40737. doi: 10.2340/actadv.v104.40737 Lina RENKHOLD 1Department of Dermatology, University Hospital Münster, …Den ganzen Artikel lesen

Pinter A, Costanzo A, Khattri S, Smith SD, Carrascosa JM, Tada Y, Riedl E, Reich A, Brnabic A, Haustrup N, Lampropoulou A, Lipkovich I, Kadziola Z, …Den ganzen Artikel lesen

Biostatistics. 2024 Oct 27:kxae039. doi: 10.1093/biostatistics/kxae039. Online ahead of print. ABSTRACT In life history analysis of data from cohort studies, it is important to address the process by which participants are identified and selected. Many health studies select or enrol individuals based on whether they have experienced certain health related events, for example, disease diagnosis or some complication from disease. Standard methods of analysis rely on assumptions concerning the independence of selection and a person's prospective life history process, given their prior history. Violations of such assumptions are common, however, and can bias estimation of process features. This has implications for the internal and external validity of cohort studies, and for the transportabilty of results to a population. In this paper, we study failure time analysis by proposing a joint model for the cohort selection process and the failure process of interest. This allows us to address both independence assumptions and the transportability of study results. It is shown that transportability cannot be guaranteed in the absence of auxiliary information on the population. Conditions that produce dependent selection and types of auxiliary data are discussed and illustrated in numerical studies. The proposed framework is applied to a study of the risk of psoriatic arthritis in persons with psoriasis. PMID:39462279 | DOI:10.1093/biostatistics/kxae039 Den ganzen Artikel lesen

J Dermatolog Treat. 2024 Dec;35(1):2420825. doi: 10.1080/09546634.2024.2420825. Epub 2024 Oct 27. ABSTRACT Introduction: Psoriasis is a chronic immune-mediated disease that can be challenging to treat, especially in patients with severe disease or high body weight. Tildrakizumab is a monoclonal antibody which inhibits IL-23, approved for moderate-to-severe psoriasis with a standard 100 mg dose. A 200 mg dose may provide greater efficacy for patients over 90 kg or with high disease burden. Methods: This multicenter, prospective study evaluated the effectiveness and safety of tildrakizumab 200 mg in patients with moderate-to-severe psoriasis, focusing on those with specific challenges: body weight over 90 kg, baseline PASI ≥20, and difficult-to-treat areas. The study also compared bio-naive versus bio-experienced and male versus female patients. Adults received tildrakizumab 200 mg subcutaneously at weeks 0 and 4, then every 12 weeks. Results: Clinical improvements were assessed using PASI, DLQI, genital PASI, and NAPSI scores. After 24 weeks, the mean PASI score dropped from 14.6 to 0.4, with PASI 90 and PASI 100 scores exceeding 80% (100.0% and 80.3%, respectively). DLQI scores improved from 14.2 to 1.8, and significant improvements were seen in genital PASI and NAPSI scores. No significant adverse events occurred. Conclusions: Tildrakizumab 200 has been shown to be an effective therapeutic option, particularly for patients with high body weight, significant disease burden, and involvement of sensitive areas with no new safety signals. PMID:39462515 | DOI:10.1080/09546634.2024.2420825 Den ganzen Artikel lesen

Microorganisms. 2024 Oct 3;12(10):2010. doi: 10.3390/microorganisms12102010. ABSTRACT The skin plays a crucial role in maintaining homeostasis and protecting against external aggressors. Recent research has highlighted the potential of probiotics and postbiotics in dermatological treatments and skincare. These beneficial microorganisms interact with the skin microbiota, modulate the immune response, and enhance the skin barrier, offering a promising therapeutic avenue for various skin conditions, such as acne, dermatitis, eczema, and psoriasis. This bibliometric study aims to analyze the global trends and scientific impact of topical probiotics in dermatology. By reviewing 106 articles published between 2013 and 2023, the study categorizes the applications of probiotics in wound healing, inflammatory skin diseases, and general skincare. The findings indicate a significant increase in publications from 2021 onwards, attributed to the heightened focus on medical research during the COVID-19 pandemic. This study also identifies the most productive countries, institutions, and authors in this field, highlighting the importance of international collaborations. The results underscore the efficacy of probiotic-based topical formulations in improving skin health, reducing inflammation, and enhancing wound healing. This comprehensive analysis supports the development of new therapeutic strategies based on topical probiotics and encourages high-quality research in this promising area. PMID:39458319 | PMC:PMC11510400 | DOI:10.3390/microorganisms12102010 Den ganzen Artikel lesen

Pharmaceutics. 2024 Sep 30;16(10):1287. doi: 10.3390/pharmaceutics16101287. ABSTRACT BACKGROUND: Baricitinib, commonly used for autoimmune diseases, is typically administered orally, which can lead to systemic adverse effects. A topical formulation could potentially offer localized therapeutic effects while minimizing these side effects. OBJECTIVES: This study focuses on developing a lipid-based topical formulation of baricitinib (BCT-OS) for treating psoriasis. METHODS: The optimized formulation was then assessed for physical, chemical, and biopharmaceutical characterization. Furthermore, the anti-inflammatory efficacy of the formulation was tested in a model of psoriasis induced by imiquimod in mice, and its tolerance was determined by the evaluation of biomechanical skin properties and an inflammation test model induced by xylol in mice. RESULTS: BCT-OS presented appropriate characteristics for skin administration in terms of pH, rheology, extensibility, and stability. The formulation also demonstrated a notable reduction in skin inflammation in the mouse model, and high tolerability without affecting the skin integrity. CONCLUSIONS: BCT-OS shows promise as an alternative treatment for psoriasis, offering localized therapeutic benefits with a potentially improved safety profile compared to systemic administration. PMID:39458616 | PMC:PMC11510483 | DOI:10.3390/pharmaceutics16101287 Den ganzen Artikel lesen

Pharmaceutics. 2024 Oct 4;16(10):1295. doi: 10.3390/pharmaceutics16101295. ABSTRACT BACKGROUND/OBJECTIVES: Implementing model-informed precision dosing (MIPD) strategies guided by population pharmacokinetic/pharmacodynamic (PK/PD) models could enhance the management of inflammatory diseases such as psoriasis. However, the extent of individual experimental data gathered during MIPD significantly influences the uncertainty in estimating individual PK/PD parameters, affecting clinical dose selection decisions. METHODS: This study proposes a methodology to individualize ustekinumab (UTK) dosing strategies for 23 Spanish patients with moderate to severe chronic plaque psoriasis., considering the uncertainty of individual parameters within a population PK/PD model. RESULTS: An indirect response model from previous research was used to describe the PK/PD relationship between UTK serum concentrations and the Psoriasis Area and Severity Index (PASI) score. A maximum inhibition drug effect (Imax) model was selected, and a first-order remission constant rate of psoriatic skin lesion (kout = 0.016 d-1) was estimated. CONCLUSIONS: The MIPD approach predicted that 35% and 26% of the patients would need an optimized and intensified dosage regimen, respectively, compared to the regimen typically used in clinical practice. This analysis demonstrated its utility as a tool for selecting personalized UTK dosing regimens in clinical practice in order to optimize the probability of achieving targeted clinical outcomes in patients with psoriasis. PMID:39458624 | PMC:PMC11510411 | DOI:10.3390/pharmaceutics16101295 Den ganzen Artikel lesen